Why the study?
How should novel oral anticoagulants be dosed in morbidly obese and obese patients?
How should novel oral anticoagulants be dosed in morbidly obese and obese patients?
Answers are grounded in this paper and cite their sources.
There is currently insufficient evidence to guide dose adjustment of novel oral anticoagulants in morbidly obese patients, highlighting a need for further research.
Due to its constantly growing incidence, obesity is an increasingly serious social and medical problem. Available data on the use of novel oral anticoagulants in morbidly obese and obese patients are very limited. However, we tried to summarize the available knowledge on the use of anticoagulants in this subpopulation of patients in everyday clinical practice. Studies on the clinical use of anticoagulants provide a poor basis for any adjustment of doses in obese patients as compared to patients with normal body weight. In our opinion, further studies are required in this particular population.
No takes yet. Share an insight, caveat, or question.
Domienik‐Karłowicz et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: